Mineral and Bone Disorders Following Renal Transplantation

  • Hatem AmerEmail author
  • Rajiv KumarEmail author


Bone disease and abnormalities in bone mineral metabolism occur in patients following renal transplantation. Bone demineralization and an increase in fractures of the hip and spine are noted. Many of the abnormalities are due to the administration of glucocorticoids on a background of pre-existing renal bone disease (either hyperparathyroidism or low-turnover bone disease). Appropriate treatment of bone disease prior to transplantation, the administration of vitamin D and its analogs and bisphosphonates, limiting the amount of steroid administered, and exploring the use of “steroid-free” immunosuppression are strategies that have a salutary effect on bone outcomes. We also discuss potential mineral and bone abnormalities that occur in live kidney donors, as it is apparent that these individuals who represent almost 30% of all renal organ donors experience alterations in calcium and phosphorus metabolism as well as changes in calciotropic hormones and phosphate-regulating factors.


Transplantation Bone disease Hyperparathyroidism Glucocorticoids Calcineurin inhibitors Fractures Paricalcitol 


  1. 1.
    Alshayeb HM, Josephson MA, Sprague SM. CKD-mineral and bone disorder management in kidney transplant recipients. Am J Kidney Dis. 2013;61(2):310–25.PubMedCrossRefGoogle Scholar
  2. 2.
    Rojas E, Carlini RG, Clesca P, Arminio A, Suniaga O, De Elguezabal K, et al. The pathogenesis of osteodystrophy after renal transplantation as detected by early alterations in bone remodeling. Kidney Int. 2003;63(5):1915–23.PubMedCrossRefGoogle Scholar
  3. 3.
    Bonomini V, Bortolotti GC, Feletti C, Scolari MP. Serial histomorphometric and histochemical bone biopsy studies in dialysis and transplantation. J Urol Nephrol (Paris). 1975;81(12):941–50.Google Scholar
  4. 4.
    Bonomini V, Feletti C, Di Felice A, Buscaroli A. Bone remodelling after renal transplantation (RT). Adv Exp Med Biol. 1984;178:207–16.PubMedCrossRefGoogle Scholar
  5. 5.
    Lehmann G, Ott U, Stein G, Steiner T, Wolf G. Renal osteodystrophy after successful renal transplantation: a histomorphometric analysis in 57 patients. Transplant Proc. 2007;39(10):3153–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Almond MK, Kwan JT, Evans K, Cunningham J. Loss of regional bone mineral density in the first 12 months following renal transplantation. Nephron. 1994;66(1):52–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Aroldi A, Ponticelli C. Skeletal complications after renal transplantation. Int J Artif Organs. 1998;21(5):251–4.PubMedCrossRefGoogle Scholar
  8. 8.
    Blaslov K, Katalinic L, Kes P, Spasovski G, Smalcelj R, Basic-Jukic N. What is the impact of immunosuppressive treatment on the post-transplant renal osteopathy? Int Urol Nephrol. 2014;46(5):1019–24.PubMedCrossRefGoogle Scholar
  9. 9.
    Brandenburg VM, Politt D, Ketteler M, Fassbender WJ, Heussen N, Westenfeld R, et al. Early rapid loss followed by long-term consolidation characterizes the development of lumbar bone mineral density after kidney transplantation. Transplantation. 2004;77(10):1566–71.PubMedCrossRefGoogle Scholar
  10. 10.
    Haffner D, Schuler U. Metabolic bone disease after renal transplantation. Curr Opin Pediatr. 2014;26(2):198–206.PubMedCrossRefGoogle Scholar
  11. 11.
    Harrington KD, Murray WR, Kountz SL, Belzer FO. Avascular necrosis of bone after renal transplantation. J Bone Joint Surg Am. 1971;53(2):203–15.PubMedCrossRefGoogle Scholar
  12. 12.
    Nehme D, Rondeau E, Paillard F, Moreau JF, Nussaume O, Kanfer A, et al. Aseptic necrosis of bone following renal transplantation: relation with hyperparathyroidism. Nephrol Dial Transplant. 1989;4(2):123–8.PubMedGoogle Scholar
  13. 13.
    Rodino MA, Shane E. Osteoporosis after organ transplantation. Am J Med. 1998;104(5):459–69.PubMedCrossRefGoogle Scholar
  14. 14.
    ter Meulen CG, Hilbrands LB, van den Bergh JP, Hermus AR, Hoitsma AJ. The influence of corticosteroids on quantitative ultrasound parameters of the calcaneus in the 1st year after renal transplantation. Osteoporos Int. 2005;16(3):255–62.PubMedCrossRefGoogle Scholar
  15. 15.
    Ugur A, Guvener N, Isiklar I, Turan M, Erdal R, Haberal M. Osteoporosis after renal transplantation: single center experience. Transplantation. 2001;71(5):645–9.PubMedCrossRefGoogle Scholar
  16. 16.
    van den Ham EC, Kooman JP, Christiaans ML, van Hooff JP. The influence of early steroid withdrawal on body composition and bone mineral density in renal transplantation patients. Transpl Int. 2003;16(2):82–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Aroldi A, Tarantino A, Montagnino G, Cesana B, Cocucci C, Ponticelli C. Effects of three immunosuppressive regimens on vertebral bone density in renal transplant recipients: a prospective study. Transplantation. 1997;63(3):380–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Briner VA, Landmann J, Brunner FP, Thiel G. Cyclosporin A-induced transient rise in plasma alkaline phosphatase in kidney transplant patients. Transpl Int. 1993;6(2):99–107.PubMedCrossRefGoogle Scholar
  19. 19.
    Campistol JM, Holt DW, Epstein S, Gioud-Paquet M, Rutault K, Burke JT. Bone metabolism in renal transplant patients treated with cyclosporine or sirolimus. Transpl Int. 2005;18(9):1028–35.PubMedCrossRefGoogle Scholar
  20. 20.
    Gaber AO, Matas AJ, Henry ML, Brennan DC, Stevens RB, Kapur S, et al. Antithymocyte globulin induction in living donor renal transplant recipients: final report of the TAILOR registry. Transplantation. 2012;94(4):331–7.PubMedCrossRefGoogle Scholar
  21. 21.
    El-Faramawi M, Rohr N, Jespersen B. Steroid-free immunosuppression after renal transplantation-long-term experience from a single centre. Nephrol Dial Transplant. 2006;21(7):1966–73.PubMedCrossRefGoogle Scholar
  22. 22.
    Webster AC, Pankhurst T, Rinaldi F, Chapman JR, Craig JC. Monoclonal and polyclonal antibody therapy for treating acute rejection in kidney transplant recipients: a systematic review of randomized trial data. Transplantation. 2006;81(7):953–65.PubMedCrossRefGoogle Scholar
  23. 23.
    Calne R, Moffatt SD, Friend PJ, Jamieson NV, Bradley JA, Hale G, et al. Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation. 1999;68(10):1613–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Ciancio G, Burke GW, Gaynor JJ, Mattiazzi A, Roohipour R, Carreno MR, et al. The use of Campath-1H as induction therapy in renal transplantation: preliminary results. Transplantation. 2004;78(3):426–33.PubMedCrossRefGoogle Scholar
  25. 25.
    Kaufman DB, Leventhal JR, Axelrod D, Gallon LG, Parker MA, Stuart FP. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction–long-term results. Am J Transplant. 2005;5(10):2539–48.PubMedCrossRefGoogle Scholar
  26. 26.
    Shapiro R, Basu A, Tan H, Gray E, Kahn A, Randhawa P, et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with thymoglobulin or campath. J Am Coll Surg. 2005;200(4):505–15; quiz A59-61.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Ciancio G, Burke GW, Gaynor JJ, Carreno MR, Cirocco RE, Mathew JM, et al. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation. 2005;80(4):457–65.PubMedCrossRefGoogle Scholar
  28. 28.
    (HHS) OUSDoHaHS. Organ Procurement and Transplantation Network; U.S. Department of Health and Human Services. 2015.Google Scholar
  29. 29.
    Horvat LD, Shariff SZ, Garg AX, Donor Nephrectomy Outcomes Research N. Global trends in the rates of living kidney donation. Kidney Int. 2009;75(10):1088–98.PubMedCrossRefGoogle Scholar
  30. 30.
    USRDS. USRDS 2015 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. In: NIH N, Bethesda: National Institutes of Health, editor. 2015.Google Scholar
  31. 31.
    Grams ME, Sang Y, Levey AS, Matsushita K, Ballew S, Chang AR, et al. Kidney-failure risk projection for the living kidney-donor candidate. N Engl J Med. 2016;374(5):411–21.PubMedCrossRefGoogle Scholar
  32. 32.
    Muzaale AD, Massie AB, Wang MC, Montgomery RA, McBride MA, Wainright JL, et al. Risk of end-stage renal disease following live kidney donation. JAMA. 2014;311(6):579–86.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Mjoen G, Hallan S, Hartmann A, Foss A, Midtvedt K, Oyen O, et al. Long-term risks for kidney donors. Kidney Int. 2014;86(1):162–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Kasiske BL, Anderson-Haag T, Israni AK, Kalil RS, Kimmel PL, Kraus ES, et al. A prospective controlled study of living kidney donors: three-year follow-up. Am J Kidney Dis. 2015;66(1):114–24.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Kasiske BL, Kumar R, Kimmel PL, Pesavento TE, Kalil RS, Kraus ES, et al. Abnormalities in biomarkers of mineral and bone metabolism in kidney donors. Kidney Int. 2016;90(4):861–8.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69(11):1945–53.PubMedCrossRefGoogle Scholar
  37. 37.
    McCarthy JT, Kumar R. Behavior of the vitamin D endocrine system in the development of renal osteodystrophy. Semin Nephrol. 1986;6(1):21–30.PubMedGoogle Scholar
  38. 38.
    McCarthy JT, Kumar R. Renal osteodystrophy. Endocrinol Metab Clin N Am. 1990;19(1):65–93.CrossRefGoogle Scholar
  39. 39.
    McCarthy JT, Rajiv K. Role of the vitamin D system in the pathogenesis of renal osteodystrophy. In: Kumar R, editor. Vitamin D: basic and clinical aspects. Dortrecht: Martinus Nijhoff Publishers; 1984. p. 611–40.CrossRefGoogle Scholar
  40. 40.
    Ghanekar H, Welch BJ, Moe OW, Sakhaee K. Post-renal transplantation hypophosphatemia: a review and novel insights. Curr Opin Nephrol Hypertens. 2006;15(2):97–104.PubMedCrossRefGoogle Scholar
  41. 41.
    Martin KJ, Olgaard K, Coburn JW, Coen GM, Fukagawa M, Langman C, et al. Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. Am J Kidney Dis. 2004;43(3):558–65.PubMedCrossRefGoogle Scholar
  42. 42.
    Bricker NS, Slatopolsky E, Reiss E, Avioli LV. Caclium, phosphorus, and bone in renal disease and transplantation. Arch Intern Med. 1969;123(5):543–53.PubMedCrossRefGoogle Scholar
  43. 43.
    London G, Coyne D, Hruska K, Malluche HH, Martin KJ. The new kidney disease: improving global outcomes (KDIGO) guidelines - expert clinical focus on bone and vascular calcification. Clin Nephrol. 2010;74(6):423–32.PubMedPubMedCentralGoogle Scholar
  44. 44.
    Malluche HH. Bone disease in renal failure. Introduction. Miner Electrolyte Metab. 1991;17(4):209–10.PubMedGoogle Scholar
  45. 45.
    Malluche HH, Ritz E, Lange HP, Kutschera L, Hodgson M, Seiffert U, et al. Bone histology in incipient and advanced renal failure. Kidney Int. 1976;9(4):355–62.PubMedCrossRefGoogle Scholar
  46. 46.
    Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Malluche H, et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 2013;28(1):2–17.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Moore C, Yee J, Malluche H, Rao DS, Monier-Faugere MC, Adams E, et al. Relationship between bone histology and markers of bone and mineral metabolism in African-American hemodialysis patients. Clin J Am Soc Nephrol. 2009;4(9):1484–93.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Malluche HH, Mawad H, Monier-Faugere MC. Effects of treatment of renal osteodystrophy on bone histology. Clin J Am Soc Nephrol. 2008;3(Suppl 3):S157–63.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Malluche HH, Monier-Faugere MC. Renal osteodystrophy: what's in a name? Presentation of a clinically useful new model to interpret bone histologic findings. Clin Nephrol. 2006;65(4):235–42.PubMedCrossRefGoogle Scholar
  50. 50.
    Qi Q, Monier-Faugere MC, Geng Z, Malluche HH. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis. 1995;26(4):622–31.PubMedCrossRefGoogle Scholar
  51. 51.
    Malluche HH, Monier-Faugere MC. The role of bone biopsy in the management of patients with renal osteodystrophy. J Am Soc Nephrol. 1994;4(9):1631–42.PubMedGoogle Scholar
  52. 52.
    Malluche HH, Mawad HW, Monier-Faugere MC. Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients. J Bone Miner Res. 2011;26(6):1368–76.PubMedCrossRefGoogle Scholar
  53. 53.
    Reiss E, Canterbury JM, Kanter A. Circulating parathyroid hormone concentration in chronic renal insufficiency. Arch Intern Med. 1969;124(4):417–22.PubMedCrossRefGoogle Scholar
  54. 54.
    Potts JT, Reita RE, Deftos LJ, Kaye MB, Richardson JA, Buckle RM, et al. Secondary hyperparathyroidism in chronic renal disease. Arch Intern Med. 1969;124(4):408–12.PubMedCrossRefGoogle Scholar
  55. 55.
    Norman ME, Mazur AT, Borden S, Gruskin A, Anast C, Baron R, et al. Early diagnosis of juvenile renal osteodystrophy. J Pediatr. 1980;97(2):226–32.PubMedCrossRefGoogle Scholar
  56. 56.
    Baron R, Mazur A, Norman M. Histomorphometric classification of juvenile renal osteodystrophy: prevalence of mineralizing defect. In: Norman AW, Schaefer K, Herrath DV, Grigoleit H-G, editors. Vitamin D: chemical, biochemical and clinical endocrinology of calcium metabolism. Berlin: Walter de Gruyter; 1982. p. 835–40.Google Scholar
  57. 57.
    Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl. 1999;73:S14–9.PubMedCrossRefGoogle Scholar
  58. 58.
    Slatopolsky E. The intact nephron hypothesis: the concept and its implications for phosphate management in CKD-related mineral and bone disorder. Kidney Int Suppl. 2011;121:S3–8.CrossRefGoogle Scholar
  59. 59.
    Slatopolsky E, Bricker NS. The role of phosphorus restriction in the prevention of secondary hyperparathyroidism in chronic renal disease. Kidney Int. 1973;4(2):141–5.PubMedCrossRefGoogle Scholar
  60. 60.
    Slatopolsky E, Brown A, Dusso A. Role of phosphorus in the pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis. 2001;37(1 Suppl 2):S54–7.PubMedCrossRefGoogle Scholar
  61. 61.
    Martin DR, Ritter CS, Slatopolsky E, Brown AJ. Acute regulation of parathyroid hormone by dietary phosphate. Am J Physiol Endocrinol Metab. 2005;289(4):E729–34.PubMedCrossRefGoogle Scholar
  62. 62.
    Slatopolsky E, Caglar S, Gradowska L, Canterbury J, Reiss E, Bricker NS. On the prevention of secondary hyperparathyroidism in experimental chronic renal disease using "proportional reduction" of dietary phosphorus intake. Kidney Int. 1972;2(3):147–51.PubMedCrossRefGoogle Scholar
  63. 63.
    Slatopolsky E, Delmez JA. Pathogenesis of secondary hyperparathyroidism. Miner Electrolyte Metab. 1995;21(1–3):91–6.PubMedGoogle Scholar
  64. 64.
    McCarthy JT, Kumar R. Renal osteodystrophy. In: Jacobson HR, Striker GE, Klahr S, editors. The principles and practice of nephrology. St. Louis: Mosby-Year Book, Inc.; 1995. p. 1032–45.Google Scholar
  65. 65.
    DeLuca HF. The kidney as an endocrine organ involved in the function of vitamin D. Am J Med. 1975;58(1):39–47.PubMedCrossRefGoogle Scholar
  66. 66.
    Eisman JA, Hamstra AJ, Kream BE, DeLuca HF. 1,25-Dihydroxyvitamin D in biological fluids: a simplified and sensitive assay. Science. 1976;193(4257):1021–3.PubMedCrossRefGoogle Scholar
  67. 67.
    Hollis BW. Assay of circulating 1,25-dihydroxyvitamin D involving a novel single-cartridge extraction and purification procedure. Clin Chem. 1986;32(11):2060–3.PubMedGoogle Scholar
  68. 68.
    Ishimura E, Nishizawa Y, Inaba M, Matsumoto N, Emoto M, Kawagishi T, et al. Serum levels of 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, and 25-hydroxyvitamin D in nondialyzed patients with chronic renal failure. Kidney Int. 1999;55(3):1019–27.PubMedCrossRefGoogle Scholar
  69. 69.
    Mason RS, Lissner D, Wilkinson M, Posen S. Vitamin D metabolites and their relationship to azotaemic osteodystrophy. Clin Endocrinol. 1980;13(4):375–85.CrossRefGoogle Scholar
  70. 70.
    Scharla S, Schmidt-Gayk H, Reichel H, Mayer E. A sensitive and simplified radioimmunoassay for 1,25-dihydroxyvitamin D3. Clin Chim Acta. 1984;142(3):325–38.PubMedCrossRefGoogle Scholar
  71. 71.
    Yumita S, Suzuki M, Akiba T, Akizawa T, Seino Y, Kurokawa K. Levels of serum 1,25(OH)2D in patients with pre-dialysis chronic renal failure. Tohoku J Exp Med. 1996;180(1):45–56.PubMedCrossRefGoogle Scholar
  72. 72.
    Coburn JW, Koppel MH, Brickman AS, Massry SG. Study of intestinal absorption of calcium in patients with renal failure. Kidney Int. 1973;3(4):264–72.PubMedCrossRefGoogle Scholar
  73. 73.
    Juttmann JR, Hagenouw-Taal JC, Lameyer LD, Ruis AM, Birkenhager JC. Intestinal calcium absorption, serum phosphate, and parathyroid hormone in patients with chronic renal failure and osteodystrophy before and during hemodialysis. Calcif Tissue Res. 1978;26(2):119–26.PubMedCrossRefGoogle Scholar
  74. 74.
    Chanard JM, Drueke T, Zingraff J, Man NK, Russo-Marie F, Funck-Brentano JL. Effects of haemodialysis on fractional intestinal absorption of calcium in uraemia. Eur J Clin Investig. 1976;6(3):261–4.CrossRefGoogle Scholar
  75. 75.
    Recker RR, Saville PD. Calcium absorption in renal failure: its relationship to blood urea nitrogen, dietary calcium intake, time on dialysis, and other variables. J Lab Clin Med. 1971;78(3):380–8.PubMedGoogle Scholar
  76. 76.
    Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121(11):4393–408.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005;16(7):2205–15.PubMedCrossRefGoogle Scholar
  78. 78.
    Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation. 2009;119(19):2545–52.PubMedPubMedCentralCrossRefGoogle Scholar
  79. 79.
    Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359(6):584–92.PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011;305(23):2432–9.PubMedPubMedCentralCrossRefGoogle Scholar
  81. 81.
    Pande S, Ritter CS, Rothstein M, Wiesen K, Vassiliadis J, Kumar R, et al. FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation. Nephron Physiol. 2006;104(1):23–32.CrossRefGoogle Scholar
  82. 82.
    Cunningham J, Fraher LJ, Clemens TL, Revell PA, Papapoulos SE. Chronic acidosis with metabolic bone disease. Effect of alkali on bone morphology and vitamin D metabolism. Am J Med. 1982;73(2):199–204.PubMedCrossRefGoogle Scholar
  83. 83.
    Eiam-ong S, Kurtzman NA. Metabolic acidosis and bone disease. Miner Electrolyte Metab. 1994;20(1–2):72–80.PubMedGoogle Scholar
  84. 84.
    Marone CC, Wong NL, Sutton RA, Dirks JH. Acidosis and renal calcium excretion in experimental chronic renal failure. Nephron. 1981;28(6):294–6.PubMedCrossRefGoogle Scholar
  85. 85.
    Seeman E, Wahner HW, Offord KP, Kumar R, Johnson WJ, Riggs BL. Differential effects of endocrine dysfunction on the axial and the appendicular skeleton. J Clin Invest. 1982;69(6):1302–9.PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Bakr AM. Bone mineral density and bone turnover markers in children with chronic renal failure. Pediatr Nephrol. 2004;19(12):1390–3.PubMedCrossRefGoogle Scholar
  87. 87.
    Cochat P, Braillon P, Feber J, Hadj-Aissa A, Dubourg L, Liponski I, et al. Body composition in children with renal disease: use of dual energy X-ray absorptiometry. Pediatr Nephrol. 1996;10(3):264–8.PubMedCrossRefGoogle Scholar
  88. 88.
    Ersoy FF. Osteoporosis in the elderly with chronic kidney disease. Int Urol Nephrol. 2007;39(1):321–31.PubMedCrossRefGoogle Scholar
  89. 89.
    Georgiou E, Virvidakis K, Douskas G, Lambrinoudaki I, Voudiklari S, Katsoudas S, et al. Body composition changes in chronic hemodialysis patients before and after hemodialysis as assessed by dual-energy x-ray absorptiometry. Metabolism. 1997;46(9):1059–62.PubMedCrossRefGoogle Scholar
  90. 90.
    Johnson DW, McIntyre HD, Brown A, Freeman J, Rigby RJ. The role of DEXA bone densitometry in evaluating renal osteodystrophy in continuous ambulatory peritoneal dialysis patients. Perit Dial Int. 1996;16(1):34–40.PubMedGoogle Scholar
  91. 91.
    Atsumi K, Kushida K, Yamazaki K, Shimizu S, Ohmura A, Inoue T. Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis. 1999;33(2):287–93.PubMedCrossRefGoogle Scholar
  92. 92.
    Ensrud KE, Lui LY, Taylor BC, Ishani A, Shlipak MG, Stone KL, et al. Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med. 2007;167(2):133–9.PubMedCrossRefGoogle Scholar
  93. 93.
    Alem AM, Sherrard DJ, Gillen DL, Weiss NS, Beresford SA, Heckbert SR, et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int. 2000;58(1):396–9.PubMedCrossRefGoogle Scholar
  94. 94.
    Ball AM, Gillen DL, Sherrard D, Weiss NS, Emerson SS, Seliger SL, et al. Risk of hip and renal fracture among dialysis transplant recipients. JAMA. 2002;288(23):3014–8.PubMedCrossRefGoogle Scholar
  95. 95.
    Chen YJ, Kung PT, Wang YH, Huang CC, Hsu SC, Tsai WC, et al. Greater risk of hip fracture in hemodialysis than in peritoneal dialysis. Osteoporos Int. 2014;25(5):1513–8.PubMedCrossRefGoogle Scholar
  96. 96.
    Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis. 2000;36(6):1115–21.PubMedCrossRefGoogle Scholar
  97. 97.
    Jadoul M, Albert JM, Akiba T, Akizawa T, Arab L, Bragg-Gresham JL, et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2006;70(7):1358–66.PubMedCrossRefGoogle Scholar
  98. 98.
    Mittalhenkle A, Gillen DL, Stehman-Breen CO. Increased risk of mortality associated with hip fracture in the dialysis population. Am J Kidney Dis. 2004;44(4):672–9.PubMedCrossRefGoogle Scholar
  99. 99.
    Rudser KD, de Boer IH, Dooley A, Young B, Kestenbaum B. Fracture risk after parathyroidectomy among chronic hemodialysis patients. JASN. 2007;18(8):2401–7.PubMedCrossRefGoogle Scholar
  100. 100.
    Stehman-Breen CO, Sherrard DJ, Alem AM, Gillen DL, Heckbert SR, Wong CS, et al. Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int. 2000;58(5):2200–5.PubMedCrossRefGoogle Scholar
  101. 101.
    Evenepoel P, Claes K, Kuypers D, Maes B, Bammens B, Vanrenterghem Y. Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrol Dial Transplant. 2004;19(5):1281–7.PubMedCrossRefGoogle Scholar
  102. 102.
    Evenepoel P, Meijers BKI, de Jonge H, Naesens M, Bammens B, Claes K, et al. Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation. Clin J Am Soc Nephrol. 2008;3(6):1829–36.PubMedPubMedCentralCrossRefGoogle Scholar
  103. 103.
    Amer H, Griffin MD, Stegall MD, Cosio FG, Park WD, Kremers WK, et al. Oral paricalcitol reduces the prevalence of posttransplant hyperparathyroidism: results of an open label randomized trial. Am J Transplant. 2013;13(6):1576–85.PubMedCrossRefGoogle Scholar
  104. 104.
    Carlini RG, Rojas E, Weisinger JR, Lopez M, Martinis R, Arminio A, et al. Bone disease in patients with long-term renal transplantation and normal renal function. Am J Kidney Dis. 2000;36(1):160–6.PubMedCrossRefGoogle Scholar
  105. 105.
    Borchhardt K, Sulzbacher I, Benesch T, Fodinger M, Sunder-Plassmann G, Haas M. Low-turnover bone disease in hypercalcemic hyperparathyroidism after kidney transplantation. Am J Transplant. 2007;7(11):2515–21.PubMedCrossRefGoogle Scholar
  106. 106.
    Monier-Faugere MC, Mawad H, Qi Q, Friedler RM, Malluche HH. High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation. J Am Soc Nephrol. 2000;11(6):1093–9.PubMedGoogle Scholar
  107. 107.
    Boot AM, Nauta J, Hokken-Koelega AC, Pols HA, de Ridder MA, de Muinck Keizer-Schrama SM. Renal transplantation and osteoporosis. Arch Dis Child. 1995;72(6):502–6.PubMedPubMedCentralCrossRefGoogle Scholar
  108. 108.
    Brandenburg VM, Ketteler M, Heussen N, Politt D, Frank RD, Westenfeld R, et al. Lumbar bone mineral density in very long-term renal transplant recipients: impact of circulating sex hormones. Osteoporos Int. 2005;16(12):1611–20.PubMedCrossRefGoogle Scholar
  109. 109.
    Brandenburg VM, Westenfeld R, Ketteler M. The fate of bone after renal transplantation. J Nephrol. 2004;17(2):190–204.PubMedGoogle Scholar
  110. 110.
    Bubenicek P, Sotornik I, Vitko S, Teplan V. Early bone mineral density loss after renal transplantation and pre-transplant PTH: a prospective study. Kidney Blood Press Res. 2008;31(3):196–202.PubMedCrossRefGoogle Scholar
  111. 111.
    Caglar M, Adeera L. Factors affecting bone mineral density in renal transplant patients. Ann Nucl Med. 1999;13(3):141–5.PubMedCrossRefGoogle Scholar
  112. 112.
    Chao SH, Tsai KS, Chieng PU, Lee PH, Lee CJ, Lee CS. Bone mineral density profile in uremic and renal transplant patients. Transplant Proc. 1994;26(4):2009–11.PubMedGoogle Scholar
  113. 113.
    Cueto-Manzano AM, Konel S, Hutchison AJ, Crowley V, France MW, Freemont AJ, et al. Bone loss in long-term renal transplantation: histopathology and densitometry analysis. Kidney Int. 1999;55(5):2021–9.PubMedCrossRefGoogle Scholar
  114. 114.
    Durieux S, Mercadal L, Orcel P, Dao H, Rioux C, Bernard M, et al. Bone mineral density and fracture prevalence in long-term kidney graft recipients. Transplantation. 2002;74(4):496–500.PubMedCrossRefGoogle Scholar
  115. 115.
    Feber J, Cochat P, Braillon P, Castelo F, Martin X, Glastre C, et al. Bone mineral density after renal transplantation in children. J Pediatr. 1994;125(6 Pt 1):870–5.PubMedCrossRefGoogle Scholar
  116. 116.
    Grotz WH, Mundinger FA, Gugel B, Exner V, Kirste G, Schollmeyer PJ. Bone-fracture and osteodensitometry with dual-energy X-ray absorptiometry in kidney-transplant recipients. Transplantation. 1994;58(8):912–5.PubMedCrossRefGoogle Scholar
  117. 117.
    Grotz WH, Mundinger FA, Gugel B, Exner VM, Kirste G, Schollmeyer PJ. Bone mineral density after kidney transplantation. A cross-sectional study in 190 graft recipients up to 20 years after transplantation. Transplantation. 1995;59(7):982–6.PubMedCrossRefGoogle Scholar
  118. 118.
    Gupta AK, Huang M, Prasad GV. Determinants of bone mineral density in stable kidney transplant recipients. J Nephrol. 2012;25(3):373–83.PubMedCrossRefGoogle Scholar
  119. 119.
    Horber FF, Casez JP, Steiger U, Czerniak A, Montandon A, Jaeger P. Changes in bone mass early after kidney transplantation. J Bone Miner Res. 1994;9(1):1–9.PubMedCrossRefGoogle Scholar
  120. 120.
    Kwan JT, Almond MK, Evans K, Cunningham J. Changes in total body bone mineral content and regional bone mineral density in renal patients following renal transplantation. Miner Electrolyte Metab. 1992;18(2–5):166–8.PubMedGoogle Scholar
  121. 121.
    Moreno A, Torregrosa JV, Pons F, Campistol JM, Martinez de Osaba MJ, Oppenheimer F. Bone mineral density after renal transplantation: long-term follow-up. Transplant Proc. 1999;31(6):2322–3.PubMedCrossRefGoogle Scholar
  122. 122.
    Nielsen HE, Melsen F, Christensen MS. Bone lesions following renal transplantation. Bone mineral density and amount of trabecular bone. Scand J Urol Nephrol Suppl. 1977;42:127–9.Google Scholar
  123. 123.
    Weisinger JR, Carlini RG, Rojas E, Bellorin-Font E. Bone disease after renal transplantation. Clin J Am Soc Nephrol. 2006;1(6):1300–13.PubMedCrossRefGoogle Scholar
  124. 124.
    Fan SL, Kumar S, Cunningham J. Long-term effects on bone mineral density of pamidronate given at the time of renal transplantation. Kidney Int. 2003;63(6):2275–9.PubMedCrossRefGoogle Scholar
  125. 125.
    Giannini S, D'Angelo A, Carraro G, Antonello A, Di Landro D, Marchini F, et al. Persistently increased bone turnover and low bone density in long-term survivors to kidney transplantation. Clin Nephrol. 2001;56(5):353–63.PubMedGoogle Scholar
  126. 126.
    Jeffery JR, Leslie WD, Karpinski ME, Nickerson PW, Rush DN. Prevalence and treatment of decreased bone density in renal transplant recipients: a randomized prospective trial of calcitriol versus alendronate. Transplantation. 2003;76(10):1498–502.PubMedCrossRefGoogle Scholar
  127. 127.
    Julian BA, Laskow DA, Dubovsky J, Dubovsky EV, Curtis JJ, Quarles LD. Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med. 1991;325(8):544–50.PubMedCrossRefGoogle Scholar
  128. 128.
    Coen G. Fracturing osteoporosis after kidney transplantation–what are the options? Nephrol Dial Transplant. 1996;11(4):567–9.PubMedCrossRefGoogle Scholar
  129. 129.
    Davidson JK, Tsakiris D, Briggs JD, Junor BJ. Osteonecrosis and fractures following renal transplantation. Clin Radiol. 1985;36(1):27–35.PubMedCrossRefGoogle Scholar
  130. 130.
    Elmstedt E, Svahn T. Skeletal complications following renal transplantation. Acta Orthop Scand. 1981;52(3):279–86.PubMedCrossRefGoogle Scholar
  131. 131.
    Evarts CM, Phalen GS. Osseous avascular necrosis associated with renal transplantation. Clin Orthop. 1971;78:330–5.PubMedCrossRefGoogle Scholar
  132. 132.
    Levine E, Erken EH, Price HI, Meyers AM, Solomon L. Osteonecrosis following renal transplantation. AJR Am J Roentgenol. 1977;128(6):985–91.PubMedCrossRefGoogle Scholar
  133. 133.
    Ramsey-Goldman R, Dunn JE, Dunlop DD, Stuart FP, Abecassis MM, Kaufman DB, et al. Increased risk of fracture in patients receiving solid organ transplants. J Bone Miner Res. 1999;14(3):456–63.PubMedCrossRefGoogle Scholar
  134. 134.
    O'Shaughnessy EA, Dahl DC, Smith CL, Kasiske BL. Risk factors for fractures in kidney transplantation. Transplantation. 2002;74(3):362–6.PubMedCrossRefGoogle Scholar
  135. 135.
    Parker CR, Freemont AJ, Blackwell PJ, Grainge MJ, Hosking DJ. Cross-sectional analysis of renal transplantation osteoporosis. J Bone Miner Res. 1999;14(11):1943–51.PubMedCrossRefGoogle Scholar
  136. 136.
    Patel S, Kwan JTC, McCloskey E, McGee G, Thomas G, Johnson D, et al. Prevalence and causes of low bone density and fractures in kidney transplant patients. J Bone Miner Res. 2001;16(10):1863–70.PubMedCrossRefGoogle Scholar
  137. 137.
    Nam JH, Moon JI, Chung SS, Kim SI, Park KI, Song YD, et al. Prevalence and risk factors for vertebral fractures in renal transplants. Transplant Proc. 2000;32(7):1877.PubMedCrossRefGoogle Scholar
  138. 138.
    Falkiewicz K, Bidzinska B, Demissie M, Boratynska M, Zmonarski SC, Tworowska K, et al. Influence of vitamin D receptor gene polymorphisms on secondary hyperparathyroidism and bone density after kidney transplantation. Transplant Proc. 2005;37(2):1023–5.PubMedCrossRefGoogle Scholar
  139. 139.
    Kanaan N, Claes K, Devogelaer JP, Vanderschueren D, Depresseux G, Goffin E, et al. Fibroblast growth factor-23 and parathyroid hormone are associated with post-transplant bone mineral density loss. CJASN. 2010;5(10):1887–92.PubMedCrossRefGoogle Scholar
  140. 140.
    Young A, Hodsman AB, Boudville N, Geddes C, Gill J, Goltzman D, et al. Bone and mineral metabolism and fibroblast growth factor 23 levels after kidney donation. Am J Kidney Dis. 2012;59(6):761–9.PubMedCrossRefGoogle Scholar
  141. 141.
    Gonzalez MT, Gonzalez C, Grino JM, Castelao AM, Marinoso ML, Serrano S, et al. Long-term evolution of renal osteodystrophy after kidney transplantation: comparative study between intact PTH levels and bone biopsy. Transplant Proc. 1990;22(4):1407–11.PubMedGoogle Scholar
  142. 142.
    Isaksson E, Sterner G. Early development of secondary hyperparathyroidism following renal transplantation.[Erratum appears in Nephron Clin Pract. 2012;121(3–4): c111]. Nephron. 2012;121(1–2):c68–72.PubMedGoogle Scholar
  143. 143.
    Kawarazaki H, Shibagaki Y, Fukumoto S, Kido R, Nakajima I, Fuchinoue S, et al. The relative role of fibroblast growth factor 23 and parathyroid hormone in predicting future hypophosphatemia and hypercalcemia after living donor kidney transplantation: a 1-year prospective observational study. Nephrol Dial Transplant. 2011;26(8):2691–5.PubMedCrossRefGoogle Scholar
  144. 144.
    Kokado Y, Takahara S, Ichimaru N, Toki K, Kyo M, Permpongkosol S, et al. Factors influencing vertebral bone density after renal transplantation. Transpl Int. 2000;13(Suppl 1):S431–5.PubMedCrossRefGoogle Scholar
  145. 145.
    Roe SD, Porter CJ, Godber IM, Hosking DJ, Cassidy MJ. Reduced bone mineral density in male renal transplant recipients: evidence for persisting hyperparathyroidism. Osteoporos Int. 2005;16(2):142–8.PubMedCrossRefGoogle Scholar
  146. 146.
    Torres A, Rodriguez AP, Concepcion MT, Garcia S, Rufino M, Martin B, et al. Parathyroid function in long-term renal transplant patients: importance of pre-transplant PTH concentrations. Nephrol Dial Transplant. 1998;13:94–7.PubMedCrossRefGoogle Scholar
  147. 147.
    Bozkaya G, Nart A, Uslu A, Onman T, Aykas A, Dogan M, et al. Impact of calcineurin inhibitors on bone metabolism in primary kidney transplant patients. Transplant Proc. 2008;40(1):151–5.PubMedCrossRefGoogle Scholar
  148. 148.
    Stein E, Ebeling P, Shane E. Post-transplantation osteoporosis. Endocrinol Metab Clin North Am. 2007;36(4):937–63.PubMedCrossRefGoogle Scholar
  149. 149.
    Westenfeld R, Schlieper G, Woltje M, Gawlik A, Brandenburg V, Rutkowski P, et al. Impact of sirolimus, tacrolimus and mycophenolate mofetil on osteoclastogenesis-implications for post-transplantation bone disease. Nephrol Dial Transplant. 2011;26(12):4115–23.PubMedCrossRefGoogle Scholar
  150. 150.
    Zand MS. Immunosuppression and immune monitoring after renal transplantation. Semin Dial. 2005;18(6):511–9.PubMedCrossRefGoogle Scholar
  151. 151.
    Vincenti F, Schena FP, Paraskevas S, Hauser IA, Walker RG, Grinyo J, et al. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant. 2008;8(2):307–16.PubMedCrossRefGoogle Scholar
  152. 152.
    Woodle ES, Peddi VR, Tomlanovich S, Mulgaonkar S, Kuo PC, Investigators TS. A prospective, randomized, multicenter study evaluating early corticosteroid withdrawal with thymoglobulin in living-donor kidney transplantation. Clin Transpl. 2010;24(1):73–83.CrossRefGoogle Scholar
  153. 153.
    Walker JK, Alloway RR, Roy-Chaudhury P, Mogilishetty G, Cardi MA, Weimert NA, et al. A prospective trial of a steroid-free/calcineurin inhibitor minimization regimen in human leukocyte antigen (HLA)-identical live donor renal transplantation. Transplantation. 2009;87(3):408–14.PubMedCrossRefGoogle Scholar
  154. 154.
    Woodle ES, Vincenti F, Lorber MI, Gritsch HA, Hricik D, Washburn K, et al. A multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under simulect, tacrolimus and sirolimus. Am J Transplant. 2005;5(1):157–66.PubMedCrossRefGoogle Scholar
  155. 155.
    de Nijs RNJ, Jacobs JWG, Bijlsma JWJ, Lems WF, Laan R, Houben HHM, et al. Prevalence of vertebral deformities and symptomatic vertebral fractures in corticosteroid treated patients with rheumatoid arthritis. Rheumatology. 2001;40(12):1375–83.PubMedCrossRefGoogle Scholar
  156. 156.
    Kalpakcioglu BB, Engelke K, Genant HK. Advanced imaging assessment of bone fragility in glucocorticoid-induced osteoporosis. Bone. 2011;48(6):1221–31.PubMedCrossRefGoogle Scholar
  157. 157.
    Ebeling PR. Approach to the patient with transplantation-related bone loss. J Clin Endocrinol Metab. 2009;94(5):1483–90.PubMedCrossRefGoogle Scholar
  158. 158.
    Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax. 2011;66(8):699–708.PubMedCrossRefGoogle Scholar
  159. 159.
    Van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15(6):993–1000.PubMedCrossRefGoogle Scholar
  160. 160.
    Thierry A, Mourad G, Buchler M, Kamar N, Villemain F, Heng AE, et al. Steroid avoidance with early intensified dosing of enteric-coated mycophenolate sodium: a randomized multicentre trial in kidney transplant recipients. Nephrol Dial Transplant. 2012;27(9):3651–9.PubMedCrossRefGoogle Scholar
  161. 161.
    Srinivas TR, Meier-Kriesche HU. Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result. Clin J Am Soc Nephrol. 2008;3(Suppl 2):S101–16.PubMedPubMedCentralCrossRefGoogle Scholar
  162. 162.
    Lee Y-J, Kim B, Lee JE, Kim Y-G, Kim DJ, Kim S-J, et al. Randomized trial of cyclosporine and tacrolimus therapy with steroid withdrawal in living-donor renal transplantation: 5-year follow-up. Transpl Int. 2010;23(2):147–54.PubMedCrossRefGoogle Scholar
  163. 163.
    Mainra R, Elder G. Review article: managing bone complications after kidney transplantation. Nephrology (Carlton). 2009;14(4):437–42.CrossRefGoogle Scholar
  164. 164.
    Palmer SC, Strippoli GF, McGregor DO. Interventions for preventing bone disease in kidney transplant recipients: a systematic review of randomized controlled trials. Am J Kidney Dis. 2005;45(4):638–49.PubMedCrossRefGoogle Scholar
  165. 165.
    Nikkel LE, Mohan S, Zhang A, McMahon DJ, Boutroy S, Dube G, et al. Reduced fracture risk with early corticosteroid withdrawal after kidney transplant. Am J Transplant. 2012;12(3):649–59.PubMedCrossRefGoogle Scholar
  166. 166.
    Kumar R. Glucocorticoid-induced osteoporosis. Curr Opin Nephrol Hypertens. 2001;10(5):589–95.PubMedCrossRefGoogle Scholar
  167. 167.
    Compston JE. Osteoporosis after liver transplantation. Liver Transpl. 2003;9(4):321–30.PubMedCrossRefGoogle Scholar
  168. 168.
    Jeon SH, Kim SJ, Kim JS, Kang HS. Immunosuppressant FK506 decreases the intracellular magnesium in the human osteoblast cell by inhibiting the ERK1/2 pathway. Life Sci. 2009;84(1–2):23–7.PubMedCrossRefGoogle Scholar
  169. 169.
    Ponticelli C, Aroldi A. Osteoporosis after organ transplantation. Lancet. 2001;357(9268):1623.PubMedCrossRefGoogle Scholar
  170. 170.
    Monegal A, Navasa M, Guanabens N, Peris P, Pons F, de Osaba MJM, et al. Bone disease after liver transplantation: a long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics. Osteoporos Int. 2001;12(6):484–92.PubMedCrossRefGoogle Scholar
  171. 171.
    Collini A, De Bartolomeis C, Barni R, Ruggieri G, Bernini M, Carmellini M. Calcineurin-inhibitor induced pain syndrome after organ transplantation. Kidney Int. 2006;70(7):1367–70.PubMedCrossRefGoogle Scholar
  172. 172.
    Villaverde V, Cantalejo M, Balsa A, Mola EM. Leg bone pain syndrome in a kidney transplant patient treated with tacrolimus (FK506). Ann Rheum Dis. 1999;58(10):653–4.PubMedPubMedCentralCrossRefGoogle Scholar
  173. 173.
    Naredo Sanchez E, Balsa Criado A, Sanz Guajardo A, Pantoja Zarza L, Martin Mola E, Gijon BJ. Leg bone pain syndrome due to cyclosporine in a renal transplant patient. Clin Exp Rheumatol. 1994;12(6):653–6.PubMedGoogle Scholar
  174. 174.
    Lan GB, Xie XB, Peng LK, Liu L, Song L, Dai HL. Current status of research on osteoporosis after solid organ transplantation: pathogenesis and management. Biomed Res Int. 2015;2015:413169.PubMedPubMedCentralGoogle Scholar
  175. 175.
    Romero DF, Buchinsky FJ, Rucinski B, Cvetkovic M, Bryer HP, Liang XG, et al. Rapamycin - a bone-sparing immunosuppressant. J Bone Miner Res. 1995;10(5):760–8.PubMedCrossRefGoogle Scholar
  176. 176.
    Alvarez-Garcia O, Carbajo-Perez E, Garcia E, Gil H, Molinos I, Rodriguez J, et al. Rapamycin retards growth and causes marked alterations in the growth plate of young rats. Pediatr Nephrol. 2007;22(7):954–61.PubMedCrossRefGoogle Scholar
  177. 177.
    Charpentier B, Medina Pestana JO, Del CRM, Rostaing L, Grinyo J, Vanrenterghem Y, et al. Long-term exposure to belatacept in recipients of extended criteria donor kidneys. Am J Transplant. 2013;13(11):2884–91.PubMedCrossRefGoogle Scholar
  178. 178.
    Dobbels F, Wong S, Min Y, Sam J, Kalsekar A. Beneficial effect of belatacept on health-related quality of life and perceived side effects: results from the BENEFIT and BENEFIT-EXT trials. Transplantation. 2014;98(9):960–8.PubMedCrossRefGoogle Scholar
  179. 179.
    Durrbach A, Pestana JM, Pearson T, Vincenti F, Garcia VD, Campistol J, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant. 2010;10(3):547–57.PubMedCrossRefGoogle Scholar
  180. 180.
    Pestana JO, Grinyo JM, Vanrenterghem Y, Becker T, Campistol JM, Florman S, et al. Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant. 2012;12(3):630–9.PubMedCrossRefGoogle Scholar
  181. 181.
    Rostaing L, Neumayer HH, Reyes-Acevedo R, Bresnahan B, Florman S, Vitko S, et al. Belatacept-versus cyclosporine-based immunosuppression in renal transplant recipients with pre-existing diabetes. Clin J Am Soc Nephrol. 2011;6(11):2696–704.PubMedPubMedCentralCrossRefGoogle Scholar
  182. 182.
    Rostaing L, Vincenti F, Grinyo J, Rice KM, Bresnahan B, Steinberg S, et al. Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study. Am J Transplant. 2013;13(11):2875–83.PubMedCrossRefGoogle Scholar
  183. 183.
    Vanrenterghem Y, Bresnahan B, Campistol J, Durrbach A, Grinyo J, Neumayer HH, et al. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation. 2011;91(9):976–83.PubMedCrossRefGoogle Scholar
  184. 184.
    Boquist L, Bergdahl L, Andersson L. Hyperparathyroidism after renal transplantation and long-term hemodialysis. Scand J Urol Nephrol. 1971;5(3):243–50.PubMedCrossRefGoogle Scholar
  185. 185.
    Evenepoel P. Recovery versus persistence of disordered mineral metabolism in kidney transplant recipients. Semin Nephrol. 2013;33(2):191–203.PubMedCrossRefGoogle Scholar
  186. 186.
    Evenepoel P, Kuypers D, Maes B, Messiaen T, Vanrenterghem Y. Persistent hyperparathyroidism after kidney transplantation requiring parathyroidectomy. Acta Otorhinolaryngol Belg. 2001;55(2):177–86.PubMedGoogle Scholar
  187. 187.
    Fleseriu M, Licata AA. Failure of successful renal transplant to produce appropriate levels of 1,25-dihydroxyvitamin D. Osteoporos Int. 2007;18(3):363–8.PubMedCrossRefGoogle Scholar
  188. 188.
    Blohme I, Eriksson A. Parathyroidectomy after renal transplantation. Scand J Urol Nephrol Suppl. 1977;42:134–6.Google Scholar
  189. 189.
    Brunt LM, Wells SA Jr. Surgical treatment of secondary hyperparathyroidism. Ann Chir Gynaecol. 1983;72(3):139–45.PubMedGoogle Scholar
  190. 190.
    Buck BA, Robertson RD. Indications for parathyroidectomy in advanced renal disease. Surg Gynecol Obstet. 1971;133(2):218–24.PubMedGoogle Scholar
  191. 191.
    Cerilli J, Limbert JG, Ferris TF, Tzagournis M. Subtotal parathyroidectomy for tertiary hyperparathyroidism thirty-two months after renal transplantation. Am J Surg. 1973;125(5):636–8.PubMedCrossRefGoogle Scholar
  192. 192.
    Chou FF, Hsieh KC, Chen YT, Lee CT. Parathyroidectomy followed by kidney transplantation can improve bone mineral density in patients with secondary hyperparathyroidism. Transplantation. 2008;86(4):554–7.PubMedCrossRefGoogle Scholar
  193. 193.
    Conzo G, Perna AF, Sinisi AA, Palazzo A, Stanzione F, Della Pietra C, et al. Total parathyroidectomy without autotransplantation in the surgical treatment of secondary hyperparathyroidism of chronic kidney disease. J Endocrinol Investig. 2012;35(1):8–13.Google Scholar
  194. 194.
    Copley JB, Wuthrich RP. Therapeutic management of post-kidney transplant hyperparathyroidism. Clin Transplant. 2011;25(1):24–39.Google Scholar
  195. 195.
    Cruzado JM, Moreno P, Torregrosa JV, Taco O, Mast R, Gomez-Vaquero C, et al. A randomized study comparing parathyroidectomy with Cinacalcet for treating hypercalcemia in kidney allograft recipients with hyperparathyroidism. J Am Soc Nephrol. 2016;27(8):2487–94.PubMedCrossRefGoogle Scholar
  196. 196.
    Dewberry LK, Weber C, Sharma J. Near total parathyroidectomy is effective therapy for tertiary hyperparathyroidism. Am Surg. 2014;80(7):646–51.PubMedGoogle Scholar
  197. 197.
    Evenepoel P, Claes K, Kuypers DR, Debruyne F, Vanrenterghem Y. Parathyroidectomy after successful kidney transplantation: a single centre study. Nephrol Dial Transplant. 2007;22(6):1730–7.PubMedCrossRefGoogle Scholar
  198. 198.
    Foley RN, Li S, Liu J, Gilbertson DT, Chen SC, Collins AJ. The fall and rise of parathyroidectomy in U.S. hemodialysis patients, 1992 to 2002. J Am Soc Nephrol. 2005;16(1):210–8.PubMedCrossRefGoogle Scholar
  199. 199.
    Garcia A, Mazuecos A, Garcia T, Gonzalez P, Ceballos M, Rivero M. Effect of parathyroidectomy on renal graft function. Transplant Proc. 2005;37(3):1459–61.PubMedCrossRefGoogle Scholar
  200. 200.
    Dahl E, Nordal KP, Halse J, Flatmark A. Pretransplant parathyroidectomy in renal failure: effects on bone histology and aluminum deposits during dialysis and after kidney transplantation. Scand J Urol Nephrol. 1992;26(3):283–8.PubMedCrossRefGoogle Scholar
  201. 201.
    Callender GG, Malinowski J, Javid M, Zhang Y, Huang H, Quinn CE, et al. Parathyroidectomy prior to kidney transplant decreases graft failure. Surgery. 2017;161(1):44–50.PubMedCrossRefGoogle Scholar
  202. 202.
    Lou I, Schneider DF, Leverson G, Foley D, Sippel R, Chen H. Parathyroidectomy is underused in patients with tertiary hyperparathyroidism after renal transplantation. Surgery. 2016;159(1):172–9.PubMedCrossRefGoogle Scholar
  203. 203.
    Querings K, Girndt M, Geisel J, Georg T, Tilgen W, Reichrath J. 25-hydroxyvitamin D deficiency in renal transplant recipients. J Clin Endocrinol Metab. 2006;91(2):526–9.PubMedCrossRefGoogle Scholar
  204. 204.
    Cozzolino M, Brancaccio D, Cannella G, Messa P, Gesualdo L, Marangella M, et al. VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH <=150 pg/mL: results of the Italian FARO survey. Nephrol Dial Transplant. 2012;27(9):3588–94.Google Scholar
  205. 205.
    Trillini M, Cortinovis M, Ruggenenti P, Reyes Loaeza J, Courville K, Ferrer-Siles C, et al. Paricalcitol for secondary hyperparathyroidism in renal transplantation. J Am Soc Nephrol. 2015;26(5):1205–14.PubMedCrossRefGoogle Scholar
  206. 206.
    Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O, et al. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature. 1993;366(6455):575–80.PubMedCrossRefGoogle Scholar
  207. 207.
    Brown EM, Hebert SC. A cloned Ca(2+)-sensing receptor: a mediator of direct effects of extracellular Ca2+ on renal function? J Am Soc Nephrol. 1995;6(6):1530–40.PubMedGoogle Scholar
  208. 208.
    Brown EM, Hebert SC. A cloned extracellular Ca(2+)-sensing receptor: molecular mediator of the actions of extracellular Ca2+ on parathyroid and kidney cells? Kidney Int. 1996;49(4):1042–6.PubMedCrossRefGoogle Scholar
  209. 209.
    Brown EM, MacLeod RJ. Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev. 2001;81(1):239–97.PubMedCrossRefGoogle Scholar
  210. 210.
    Chou YH, Pollak MR, Brandi ML, Toss G, Arnqvist H, Atkinson AB, et al. Mutations in the human Ca(2+)-sensing-receptor gene that cause familial hypocalciuric hypercalcemia. Am J Hum Genet. 1995;56(5):1075–9.PubMedPubMedCentralGoogle Scholar
  211. 211.
    Quinn SJ, Ye CP, Diaz R, Kifor O, Bai M, Vassilev P, et al. The Ca2+−sensing receptor: a target for polyamines. Am J Phys. 1997;273(4 Pt 1):C1315–23.CrossRefGoogle Scholar
  212. 212.
    Riccardi D, Park J, Lee WS, Gamba G, Brown EM, Hebert SC. Cloning and functional expression of a rat kidney extracellular calcium/polyvalent cation-sensing receptor. Proc Natl Acad Sci U S A. 1995;92(1):131–5.PubMedPubMedCentralCrossRefGoogle Scholar
  213. 213.
    Zhang C, Miller CL, Gorkhali R, Zou J, Huang K, Brown EM, et al. Molecular basis of the extracellular ligands mediated signaling by the calcium sensing receptor. Front Physiol. 2016;7:441.PubMedPubMedCentralGoogle Scholar
  214. 214.
    Nemeth EF. Calcimimetic and calcilytic drugs: just for parathyroid cells? Cell Calcium. 2004;35(3):283–9.PubMedCrossRefGoogle Scholar
  215. 215.
    Nemeth EF, Heaton WH, Miller M, Fox J, Balandrin MF, Van Wagenen BC, et al. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther. 2004;308(2):627–35.PubMedCrossRefGoogle Scholar
  216. 216.
    Al-Moasseb Z, Aitken E. Natural history of serum calcium and parathyroid hormone following renal transplantation. Transplant Proc. 2016;48(10):3285–91.PubMedCrossRefGoogle Scholar
  217. 217.
    Jeon HJ, Kim H, Yang J. Bone disease in post-transplant patients. Curr Opin Endocrinol Diabetes Obes. 2015;22(6):452–8.Google Scholar
  218. 218.
    Komaba H, Fukagawa M. Basic and clinical aspects of calcimimetics. Calcimimetics : a promising treatment for persistent hypercalcemia after kidney transplantation. Clin Calcium. 2008;18(1):60–6.PubMedGoogle Scholar
  219. 219.
    Leca N, Laftavi M, Gundroo A, Kohli R, Min I, Karam J, et al. Early and severe hyperparathyroidism associated with hypercalcemia after renal transplant treated with cinacalcet. Am J Transplant. 2006;6(10):2391–5.PubMedCrossRefGoogle Scholar
  220. 220.
    Leonard N, Brown JH. Persistent and symptomatic post-transplant hyperparathyroidism: a dramatic response to cinacalcet. Nephrol Dial Transplant. 2006;21(6):1736.PubMedCrossRefGoogle Scholar
  221. 221.
    Muirhead N, Zaltman JS, Gill JS, Churchill DN, Poulin-Costello M, Mann V, et al. Hypercalcemia in renal transplant patients: prevalence and management in Canadian transplant practice. Clin Transpl. 2014;28(2):161–5.CrossRefGoogle Scholar
  222. 222.
    Sharma AK, Masterson R, Holt SG, Tan SJ, Hughes PD, Chu M, et al. Impact of cinacalcet pre-transplantation on mineral metabolism in renal transplant recipients. Nephrology (Carlton). 2016;21(1):46–54.CrossRefGoogle Scholar
  223. 223.
    Torregrosa JV, Barros X. Management of hypercalcemia after renal transplantation. Nefrologia. 2013;33(6):751–7.PubMedGoogle Scholar
  224. 224.
    Apostolou T, Kollia K, Damianou L, Kaitsioti H, Kotsiev V, Dracopoulos S, et al. Hypercalcemia due to resistant hyperparathyroidism in renal transplant patients treated with the calcimimetic agent cinacalcet. Transplant Proc. 2006;38(10):3514–6.PubMedCrossRefGoogle Scholar
  225. 225.
    Bahner U, Brandl M, Nies C, Schmidt-Gayk H. Use of cinacalcet HCl to achieve the recommended targets of bone metabolism in a patient with therapy-resistant renal hyperparathyroidism. J Ren Nutr. 2008;18(4):383–8.PubMedCrossRefGoogle Scholar
  226. 226.
    Bergua C, Torregrosa JV, Cofan F, Oppenheimer F. Cinacalcet for the treatment of hypercalcemia in renal transplanted patients with secondary hyperparathyroidism. Transplant Proc. 2007;39(7):2254–5.PubMedCrossRefGoogle Scholar
  227. 227.
    Bergua C, Torregrosa JV, Fuster D, Gutierrez-Dalmau A, Oppenheimer F, Campistol JM. Effect of cinacalcet on hypercalcemia and bone mineral density in renal transplanted patients with secondary hyperparathyroidism. Transplantation. 2008;86(3):413–7.PubMedCrossRefGoogle Scholar
  228. 228.
    Borchhardt KA, Diarra D, Sulzbacher I, Benesch T, Haas M, Sunder-Plassmann G. Cinacalcet decreases bone formation rate in hypercalcemic hyperparathyroidism after kidney transplantation. Am J Nephrol. 2010;31(6):482–9.PubMedCrossRefGoogle Scholar
  229. 229.
    Borchhardt KA, Heinzl H, Mayerwoger E, Horl WH, Haas M, Sunder-Plassmann G. Cinacalcet increases calcium excretion in hypercalcemic hyperparathyroidism after kidney transplantation. Transplantation. 2008;86(7):919–24.PubMedCrossRefGoogle Scholar
  230. 230.
    Cho ME, Duan Z, Chamberlain CE, Reynolds JC, Ring MS, Mannon RB. Cinacalcet improves bone density in post-kidney transplant hyperparathyroidism. Transplant Proc. 2010;42(9):3554–8.PubMedPubMedCentralCrossRefGoogle Scholar
  231. 231.
    Cohen JB, Gordon CE, Balk EM, Francis JM. Cinacalcet for the treatment of hyperparathyroidism in kidney transplant recipients: a systematic review and meta-analysis. Transplantation. 2012;94(10):1041–8.PubMedCrossRefGoogle Scholar
  232. 232.
    Copley JB, Germain M, Stern L, Pankewycz O, Katznelson S, Shah T, et al. Evaluation of cinacalcet HCl treatment after kidney transplantation. Transplant Proc. 2010;42(7):2503–8.PubMedCrossRefGoogle Scholar
  233. 233.
    Coyne DW, Delos SR. Evaluating the safety and rationale for cinacalcet posttransplant hyperparathyroidism and hypercalcemia. Am J Transplant. 2014;14(11):2446–7.PubMedCrossRefGoogle Scholar
  234. 234.
    de Francisco AL. New strategies for the treatment of hyperparathyroidism incorporating calcimimetics. Expert Opin Pharmacother. 2008;9(5):795–811.PubMedCrossRefGoogle Scholar
  235. 235.
    Dong BJ. Cinacalcet: an oral calcimimetic agent for the management of hyperparathyroidism. Clin Ther. 2005;27(11):1725–51.PubMedCrossRefGoogle Scholar
  236. 236.
    El-Amm JM, Doshi MD, Singh A, Migdal S, Morawski K, Sternbauer D, et al. Preliminary experience with cinacalcet use in persistent secondary hyperparathyroidism after kidney transplantation. Transplantation. 2007;83(5):546–9.PubMedCrossRefGoogle Scholar
  237. 237.
    Evenepoel P, Cooper K, Holdaas H, Messa P, Mourad G, Olgaard K, et al. A randomized study evaluating cinacalcet to treat hypercalcemia in renal transplant recipients with persistent hyperparathyroidism. Am J Transplant. 2014;14(11):2545–55.PubMedCrossRefGoogle Scholar
  238. 238.
    Gomez Marques G, Obrador Mulet A, Vilar Gimeno A, Pascual Felip MJ, Alarcon Zurita A, Molina Guasch M, et al. Treatment with cinacalcet of secondary hyperparathyroidism after renal transplantation. Transplant Proc. 2009;41(6):2139–43.PubMedCrossRefGoogle Scholar
  239. 239.
    Guerra R, Auyanet I, Fernandez EJ, Perez MA, Bosch E, Ramirez A, et al. Hypercalcemia secondary to persistent hyperparathyroidism in kidney transplant patients: analysis after a year with cinacalcet. J Nephrol. 2011;24(1):78–82.PubMedCrossRefGoogle Scholar
  240. 240.
    Henschkowski J, Bischoff-Ferrari HA, Wuthrich RP, Serra AL. Renal function in patients treated with cinacalcet for persistent hyperparathyroidism after kidney transplantation. Kidney Blood Press Res. 2011;34(2):97–103.PubMedCrossRefGoogle Scholar
  241. 241.
    Kamar N, Gennero I, Spataru L, Esposito L, Guitard J, Lavayssiere L, et al. Pharmacodynamic effects of cinacalcet after kidney transplantation: once- versus twice-daily dose. Nephrol Dial Transplant. 2008;23(11):3720–6.PubMedCrossRefGoogle Scholar
  242. 242.
    Ketteler M, Martin KJ, Cozzolino M, Goldsmith D, Sharma A, Khan S, et al. Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study. Nephrol Dial Transplant. 2012;27(5):1942–9.PubMedCrossRefGoogle Scholar
  243. 243.
    Kruse AE, Eisenberger U, Frey FJ, Mohaupt MG. Effect of cinacalcet cessation in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant. 2007;22(8):2362–5.PubMedCrossRefGoogle Scholar
  244. 244.
    Nakai K, Fujii H, Yoshikawa M, Kono K, Yonekura Y, Goto S, et al. Effect of cinacalcet cessation on hyperparathyroidism in kidney transcaplant patients after long-term dialysis therapy. Clin Exp Nephrol. 2015;19(6):1184–8.PubMedCrossRefGoogle Scholar
  245. 245.
    Grotz W, Nagel C, Poeschel D, Cybulla M, Petersen KG, Uhl M, et al. Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol. 2001;12(7):1530–7.PubMedGoogle Scholar
  246. 246.
    Haas M, Leko-Mohr Z, Roschger P, Kletzmayr J, Schwarz C, Mitterbauer C, et al. Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney Int. 2003;63(3):1130–6.PubMedCrossRefGoogle Scholar
  247. 247.
    Coco M, Pullman J, Cohen HW, Lee S, Shapiro C, Solorzano C, et al. Effect of risedronate on bone in renal transplant recipients. J Am Soc Nephrol. 2012;23(8):1426–37.PubMedPubMedCentralCrossRefGoogle Scholar
  248. 248.
    El-Agroudy AE, El-Husseini AA, El-Sayed M, Mohsen T, Ghoneim MA. A prospective randomized study for prevention of postrenal transplantation bone loss. Kidney Int. 2005;67(5):2039–45.PubMedCrossRefGoogle Scholar
  249. 249.
    Nowacka-Cieciura E, Cieciura T, Baczkowska T, Kozinska-Przybyl O, Tronina O, Chudzinski W, et al. Bisphosphonates are effective prophylactic of early bone loss after renal transplantation. Transplant Proc. 2006;38(1):165–7.PubMedCrossRefGoogle Scholar
  250. 250.
    Torregrosa JV, Fuster D, Gentil MA, Marcen R, Guirado L, Zarraga S, et al. Open-label trial: effect of weekly risedronate immediately after transplantation in kidney recipients. Transplantation. 2010;89(12):1476–81.PubMedCrossRefGoogle Scholar
  251. 251.
    Abediazar S, Nakhjavani MR. Effect of alendronate on early bone loss of renal transplant recipients. Transplant Proc. 2011;43(2):565–7.PubMedCrossRefGoogle Scholar
  252. 252.
    Friedlander MA, Lemke JH, Horst RL. The effect of uninephrectomy on mineral metabolism in normal human kidney donors. Am J Kidney Dis. 1988;11(5):393–401.PubMedCrossRefGoogle Scholar
  253. 253.
    Gossmann J, Wilhelm A, Kachel HG, Jordan J, Sann U, Geiger H, et al. Long-term consequences of live kidney donation follow-up in 93% of living kidney donors in a single transplant center. Am J Transplant. 2005;5(10):2417–24.PubMedCrossRefGoogle Scholar
  254. 254.
    Westerberg PA, Ljunggren O, Larsson TE, Wadstrom J, Linde T. Fibroblast growth factor-23 and mineral metabolism after unilateral nephrectomy. Nephrol Dial Transplant. 2010;25(12):4068–71.PubMedCrossRefGoogle Scholar
  255. 255.
    Ponte B, Trombetti A, Hadaya K, Ernandez T, Fumeaux D, Iselin C, et al. Acute and long term mineral metabolism adaptation in living kidney donors: a prospective study. Bone. 2014;62:36–42.PubMedCrossRefGoogle Scholar
  256. 256.
    Huan Y, Kapoor S, Deloach S, Ommen E, Meyers K, Townsend RR. Changes in biomarkers associated with living kidney donation. Am J Nephrol. 2013;38(3):212–7.PubMedCrossRefGoogle Scholar
  257. 257.
    Khosla S. Odanacatib: location and timing are everything. J Bone Miner Res. 2012;27(3):506–8.PubMedCrossRefGoogle Scholar
  258. 258.
    Riggs BL, Melton LJ 3rd. Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res. 2002;17(1):11–4.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Division of Nephrology and Hypertension, Department of Internal MedicineMayo ClinicRochesterUSA
  2. 2.Division of Nephrology and Hypertension, Departments of Internal Medicine, Biochemistry, and Molecular BiologyMayo ClinicRochesterUSA

Personalised recommendations